乳房再発スコア検査の世界市場

乳房再発スコア検査の世界市場は2030年までに4億1,410万米ドルに達する見込み

2024年に2億4,900万米ドルと推定される乳房再発スコア検査の世界市場は、2024～2030年の分析期間においてCAGR 8.8%で成長し、2030年には4億1,410万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるステージ1乳がん適応症は、CAGR 10.3%を記録し、分析期間終了までに1億5,840万米ドルに達すると予測されます。ステージ2の乳がん適応症セグメントの成長率は、分析期間中CAGR 9.5%と推定されます。

米国市場は6,790万米ドルと推定される一方、中国はCAGR 13.9％で成長すると予測される

米国の乳房再発スコア検査市場は、2024年に6,790万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9,150万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.4％と8.5％と予測されています。欧州では、ドイツがCAGR 5.9%で成長すると予測されています。

世界の乳房再発スコア検査市場- 主要動向と促進要因のまとめ

ゲノムプロファイリングは乳がんの予後と治療計画にどのような革命をもたらすか？

乳房再発スコア検査は、Oncotype DXのようなゲノムアッセイと最もよく関連しており、臨床医が乳がんの再発リスクを評価し、術後補助療法について重要な決定を下す方法を劇的に変えました。この検査は、がん関連遺伝子の特定のパネル（通常21遺伝子）の発現を評価し、初回治療から10年以内の遠隔がん再発の可能性を推定する個別化された再発スコアを作成します。腫瘍の大きさ、リンパ節転移、ホルモン受容体の状態などの臨床的・病理学的特徴に大きく依存する従来の予後予測ツールとは異なり、乳房再発スコア検査は腫瘍生物学に対する分子レベルの洞察を提供します。これにより、腫瘍医は患者を低リスク、中間リスク、高リスクのカテゴリーに層別化し、それに応じて治療計画を調整することができます。例えば、再発スコアが低い患者は、しばしば化学療法を見送ることができ、その結果、生存成績を損なうことなく、かなりの副作用を避けることができます。これは、乳がん治療における重要なパラダイムシフトであり、画一的なプロトコールよりも個別化された治療を重視するプレシジョン・オンコロジーへと移行しています。TAILORxやRxPONDERのような画期的な臨床試験から得られた臨床的証拠の積み重ねが、この検査の臨床的有用性を検証し、その結果に対する医師と患者の信頼を高めています。この検査の有用性に対する認識が高まるにつれて、早期ホルモン受容体陽性、HER2陰性乳がんの標準治療プロトコールに組み込まれることが多くなっています。その結果、臨床転帰が改善されるだけでなく、患者の満足度や生活の質も向上しています。この検査はまた、より費用対効果の高い治療計画を可能にし、不必要な治療介入を減らすことで、価値ベースのヘルスケアへのシフトにも合致します。

臨床ガイドラインと保険償還政策は、どのような役割を担っているのでしょうか？

乳房再発スコア検査の臨床ガイドラインや保険償還の枠組みへの統合が進んでいることは、乳房再発スコア検査の世界の普及を加速する上で重要な役割を果たしています。米国臨床腫瘍学会（American Society of Clinical Oncology、ASCO）、全米総合がんネットワーク（National Comprehensive Cancer Network、NCCN）、ザンクトガレン国際専門家コンセンサス（St.Gallen International Expert Consensus）などの権威ある団体が、ホルモン受容体陽性、HER2陰性乳がんを管理するための正式なガイドラインにこの検査を組み込んでいます。これらの支持は、この検査に強い臨床的信頼性を与え、世界中の腫瘍医にルーチンの診断ツールとして採用するよう促しています。同時に、特に米国、カナダ、欧州の一部の公的・民間保険会社の多くが、患者の転帰を改善し、過剰治療を最小限に抑えるというこの検査の長期的価値を認め、保険償還を承認しました。償還政策は検査利用に直接的な影響を及ぼし、特に中央集権的なヘルスケアシステムを持つ国々では、承認された診断検査が広く採用される可能性が高いです。さらに、保険適用範囲の拡大は、十分なサービスを受けていない人々の検査へのアクセスを容易にし、精密腫瘍学をより公平なものにしています。また、不必要な化学療法や入院、治療に関連する副作用の長期管理にかかるコストを大幅に削減できることを示す経済評価も、政策決定の指針となっています。新興市場では、現地の規制機関が臨床データや費用対効果報告書を評価するにつれて、このようなゲノム検査を公衆衛生戦略に組み込む動きは緩やかではあるが、着実に増加しています。さらに、製薬企業や診断薬企業は、検査採用のための道筋を確立するために、保健省や支払者と積極的に関与しています。医療上の必要性、政策的支援、コスト抑制の目的が一致することで、現代のがん医療における乳房再発スコア検査の位置づけは確固たるものとなっています。

技術の進歩は検査の精度と世界のアクセシビリティを高めているか？

分子診断技術の進化は、Breast Recurrence Score Testsの精度、拡張性、アクセス性を大きく向上させました。もともとは集中型ラボでのみ処理され、長い納期を要していましたが、新しいバージョンでは、検体処理の合理化、遺伝子発現解析の高速化、正確な再発リスク算出を保証するアルゴリズムの堅牢化などの恩恵を受けています。RNA抽出技術やリアルタイムPCRプラットフォームの改良により、少量の生検サンプルからでも再現性の高い結果が得られるようになり、この検査は臨床場面においてより汎用性の高いものとなっています。技術革新はまた、コア針生検やホルマリン固定パラフィン包埋組織など、使用可能な検体の種類を拡大し、検査実施のロジスティクスをさらに簡素化しました。ゲノムデータベースが増加し、機械学習が腫瘍学研究に組み込まれるようになると、再発スコアリングの将来的な強化は、さらに個別化されたリスク評価のために、患者の人口統計学、併存疾患、免疫プロファイルなどの追加データも取り込む可能性があります。アクセシビリティの面では、診断開発企業と地域の病理検査室とのパートナーシップにより、分散型検査モデルが可能になりつつあります。デジタル病理検査やクラウドベースのデータ転送システムは、遠隔地からのコンサルテーションやピアレビューも容易にし、都市部と地方のがんセンター間のギャップを埋めています。検査機器の小型化と自動ゲノム解析の登場により、小規模なヘルスケア施設でもこれらの検査を高い精度で提供することが可能になっています。これらの技術革新を総称すると、患者集団全体で一貫した性能を保証するだけでなく、世界的に検査の利用可能性を拡大する上で重要な役割を果たすことになります。

乳房再発スコア検査の世界の拡大を促進する主な市場要因とは？

乳房再発スコア検査市場の成長は、がん治療プロトコルの変化、技術の成熟度、患者の期待の変化に直結するいくつかの要因によって牽引されています。主要な促進要因は、乳がん罹患率の世界の上昇であり、特に若年層や開発途上地域における認識と早期診断が急速に向上しています。このため、治療を個別化し、過剰治療による身体的、精神的、経済的負担を回避できるツールに対する強い需要が生まれています。同時に、早期乳がんにおける化学療法を中心とした治療の漸減へのシフトは、再発スコア検査を重要な意思決定補助ツールとして位置づけています。ヘルスケアプロバイダーは、実用的な洞察を提供する診断ツールをますます求めており、乳房再発スコア検査は、臨床的に検証され、解釈しやすい結果を提供することで、その役割を果たし、治療経路に直接影響を与えます。さらに、情報に精通した患者集団の増加により、治療における透明性と精度が要求されるようになり、腫瘍医はゲノム検査を単なる推奨ではなく、標準治療として採用するようになっています。医療提供者側では、集学的な腫瘍委員会と価値ベースのヘルスケアモデルが、リソースの利用と転帰を最適化するために検査の利用をさらに促進しています。もう一つの重要な市場勢力は、戦略的パートナーシップ、啓蒙キャンペーン、臨床医教育プログラムを通じて、世界なフットプリントを拡大する診断薬企業の積極的な役割です。このような努力は、特にアジア太平洋地域や中南米地域で大きな影響を及ぼしており、現地での検証研究や規制当局による承認が勢いを増しています。最後に、バイオマーカーに基づく治療からリスク層別化まで、日常的ながん診療にゲノミクスを統合しようという広範な動きが、再発スコア検査の持続的成長のための肥沃な環境を作り出しています。疫学的要因、臨床的要因、経済的要因、技術的要因など、相互に関連し合うこれらの要因が相まって、乳房再発スコア検査の世界市場は堅調な上昇軌道を維持しています。

セグメント

適応症（ステージ1乳がん適応症、ステージ2乳がん適応症、エストロゲン受容体陽性がん適応症、リンパ節転移陰性がん適応症）、エンドユーザー（病院エンドユーザー、専門がんセンターエンドユーザー、その他エンドユーザー）

調査対象企業の例

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Breast Recurrence Score Test Market to Reach US$414.1 Million by 2030

The global market for Breast Recurrence Score Test estimated at US$249.0 Million in the year 2024, is expected to reach US$414.1 Million by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Stage 1 Breast Cancer Indication, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$158.4 Million by the end of the analysis period. Growth in the Stage 2 Breast Cancer Indication segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 13.9% CAGR

The Breast Recurrence Score Test market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$91.5 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Breast Recurrence Score Test Market - Key Trends & Drivers Summarized

How Is Genomic Profiling Revolutionizing Breast Cancer Prognosis and Treatment Planning?

The Breast Recurrence Score Test, most commonly associated with genomic assays like Oncotype DX, has dramatically transformed how clinicians assess the risk of breast cancer recurrence and make critical decisions about adjuvant therapy. This test evaluates the expression of a specific panel of cancer-related genes-typically 21 genes-to produce a personalized recurrence score that estimates the likelihood of distant cancer recurrence within ten years of initial treatment. Unlike traditional prognostic tools that rely heavily on clinical and pathological features such as tumor size, lymph node involvement, and hormone receptor status, the Breast Recurrence Score Test provides a molecular-level insight into tumor biology. This enables oncologists to better stratify patients into low, intermediate, or high-risk categories, tailoring treatment plans accordingly. For example, patients with a low recurrence score can often forgo chemotherapy, thus avoiding its considerable side effects without compromising survival outcomes. This has marked a significant paradigm shift in breast cancer care, moving toward precision oncology that emphasizes individualized treatment over one-size-fits-all protocols. The growing body of clinical evidence from landmark trials such as TAILORx and RxPONDER has validated the clinical utility of the test, boosting physician and patient confidence in its results. As awareness of the test’s capabilities grows, it is increasingly being integrated into standard care protocols for early-stage, hormone receptor-positive, HER2-negative breast cancer. The result is not just improved clinical outcomes, but enhanced patient satisfaction and quality of life. The test also aligns with the shift toward value-based healthcare, by enabling more cost-effective treatment planning and reducing unnecessary therapeutic interventions.

What Role Are Clinical Guidelines and Reimbursement Policies Playing in Driving Adoption?

The increasing integration of the Breast Recurrence Score Test into clinical guidelines and insurance reimbursement frameworks has played a critical role in accelerating its global adoption. Esteemed bodies such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the St. Gallen International Expert Consensus have incorporated the test into their formal guidelines for managing hormone receptor-positive, HER2-negative breast cancer. These endorsements have lent strong clinical credibility to the test, encouraging oncologists across the globe to adopt it as a routine diagnostic tool. In tandem, many public and private insurers-particularly in the U.S., Canada, and parts of Europe-have approved reimbursement for the test, recognizing its long-term value in improving patient outcomes and minimizing overtreatment. Reimbursement policies have a direct influence on test utilization, especially in countries with centralized healthcare systems, where approved diagnostic tests are more likely to be widely adopted. Moreover, expanding insurance coverage has facilitated access to the test for underserved populations, making precision oncology more equitable. Policy decisions have also been guided by economic evaluations that show the test can significantly reduce the costs associated with unnecessary chemotherapy, hospital stays, and long-term management of treatment-related side effects. In emerging markets, the inclusion of such genomic assays in public health strategies is slower but steadily increasing, as local regulatory bodies assess clinical data and cost-effectiveness reports. Additionally, pharmaceutical companies and diagnostic firms are actively engaging with health ministries and payers to establish pathways for test adoption. The alignment of medical necessity, policy support, and cost-containment objectives has solidified the Breast Recurrence Score Test’s place in contemporary cancer care.

Are Technological Advancements Enhancing Test Accuracy and Global Accessibility?

The evolution of molecular diagnostics technology has greatly enhanced the accuracy, scalability, and accessibility of Breast Recurrence Score Tests. Originally processed only in centralized labs with long turnaround times, newer iterations benefit from streamlined sample processing, faster gene expression analysis, and increasingly robust algorithms that ensure precise recurrence risk calculation. The improvement in RNA extraction techniques and real-time PCR platforms has led to more reproducible results, even from small biopsy samples, thus making the test more versatile across clinical scenarios. Technological innovation has also expanded the range of usable specimen types, including core needle biopsies and formalin-fixed paraffin-embedded tissues, further simplifying the logistics of test administration. As genomic databases grow and machine learning becomes more integrated into oncology research, future enhancements in recurrence scoring may also incorporate additional data such as patient demographics, comorbidities, and immune profiles for even more individualized risk assessment. In terms of accessibility, partnerships between diagnostic developers and regional pathology labs are enabling decentralized testing models, allowing quicker turnaround times and lowering the barrier to adoption in lower-resource settings. Digital pathology and cloud-based data transfer systems also facilitate remote consultation and peer review, bridging the gap between urban and rural cancer centers. The miniaturization of lab instrumentation and the advent of automated genomic analysis are making it feasible for smaller healthcare facilities to offer these tests with high accuracy. Collectively, these innovations not only ensure consistent performance across patient populations but also play a crucial role in scaling up test availability globally-making personalized breast cancer care a tangible reality for more women, regardless of geographic location.

What Key Market Forces Are Driving the Expansion of Breast Recurrence Score Testing Worldwide?

The growth in the Breast Recurrence Score Test market is driven by several factors directly linked to changing cancer care protocols, technological maturity, and shifting patient expectations. A major driver is the global rise in breast cancer incidence, particularly among younger populations and in developing regions where awareness and early diagnosis are rapidly improving. This has created a strong demand for tools that can personalize treatment and avoid the physical, emotional, and financial toll of overtreatment. Concurrently, the shift toward de-escalation of therapy-especially chemotherapy-in early-stage breast cancer has positioned recurrence score tests as critical decision-making aids. Healthcare providers are increasingly seeking diagnostic tools that provide actionable insights, and the Breast Recurrence Score Test fits that role by delivering clinically validated, easy-to-interpret results that directly influence treatment pathways. Moreover, a growing population of well-informed patients is demanding transparency and precision in their care, leading oncologists to adopt genomic testing not just as a recommendation, but as a standard of care. On the provider side, multi-disciplinary tumor boards and value-based healthcare models are further promoting test usage to optimize resource utilization and outcomes. Another important market force is the active role of diagnostic companies in expanding their global footprint through strategic partnerships, awareness campaigns, and clinician education programs. These efforts are particularly impactful in Asia-Pacific and Latin American regions, where local validation studies and regulatory approvals are gaining momentum. Finally, the broader movement toward integrating genomics into routine oncology practice-from biomarker-based treatment to risk stratification-has created a fertile environment for the sustained growth of recurrence score testing. These interconnected factors-epidemiological, clinical, economic, and technological-are collectively ensuring that the global market for Breast Recurrence Score Tests remains on a robust upward trajectory.

SCOPE OF STUDY:

The report analyzes the Breast Recurrence Score Test market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication, Lymph-Node-Negative Cancer Indication); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Breast Recurrence Score Test - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Precision Oncology Throws the Spotlight on Breast Recurrence Score Tests as Prognostic Tools
  • Shift Toward Personalized Breast Cancer Treatment Spurs Growth in Genomic Recurrence Risk Testing
  • Here's How Clinical Guidelines Are Driving Adoption of Recurrence Score Tests to Inform Chemotherapy Decisions
  • Expanding Use in Early-Stage HR-Positive, HER2-Negative Breast Cancer Strengthens the Business Case for Risk Stratification
  • Increased Physician and Patient Awareness Fuels Demand for Evidence-Based, Genomic-Driven Treatment Planning
  • Here's the Story: How TAILORx and RxPONDER Trial Results Are Validating Clinical Utility Across Demographics
  • Integration with Electronic Health Records and Oncology Decision Support Systems Enhances Workflow Efficiency
  • Growing Emphasis on Avoiding Overtreatment Supports the Economic Value Proposition of Recurrence Score Testing
  • Global Expansion of Molecular Pathology Labs Enables Broader Access in Developed and Emerging Markets
  • Rising Incidence of Breast Cancer Worldwide Expands the Addressable Market for Genomic Recurrence Assays
  • Innovation in Liquid Biopsy and Multi-Gene Panels May Disrupt or Complement Current Recurrence Score Test Models
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Breast Recurrence Score Test Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Stage 1 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Stage 2 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Lymph-Node-Negative Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: India 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION